Cookie Preference

This website uses cookies to improve user experience. Please select an option.  Privacy Policy

No cookies except for those necessary for technical reasons are set.

Startups 2018

Emerging Startup

Pantherna Therapeutics GmbH

Dr Klaus Giese, Dr Jörg Kaufmann, Dr Oliver Keil, Dr Gerrit Maass

Innovation & Business Idea

Pantherna Therapeutics is a biopharmaceutical company developing first-in-class therapeutics for vascular diseases by restoring endothelial cell function.

Customers / Target Market

Biotech & Big Pharma


Biotech & Big Pharma (Nucleic acid based Therapeutics)

Intellectual Property Status

Patent applications in preparation

Development Status & Future Steps

Research & Preclinical

Exit Strategy

Trade sale & IPO

Team Description

Dr. Klaus Giese, CEO. Former CEO/CSO, Erdmann Technologies, Berlin; CSO, Silence Therapeutics, London/Berlin; Senior Scientist, Chiron Corporation, Emeryville; Scientist, HHMI, Univ. of California, San Francisco (UCSF); PhD Biochemistry, Berlin. Dr. Jörg Kaufmann, CSO. Former CSO, Silence Therapeutics, London/Berlin; Senior Scientist, Chiron Corporation, Emeryville; Group Leader Institute of Tumor Biology (IMT), Marburg; Postdoctoral Fellow, HHMI, Univ. of California, Los Angeles (UCLA), PhD Molecular Genetics, Marburg. Dr. Oliver Keil, COO. Former Head of CMC, Silence Therapeutics, London/Berlin; Head of Chemistry & Formulation, G.O.T. Therapeutics, Berlin; Postdoctoral Fellow/ Group leader Non-viral Gene Transfer, University of Düsseldorf, PhD Chemistry, Wuppertal. Dr. Gerrit Maass, CFO. Former CEO/CFO Erdmann Technologies, Berlin; General Counsel at MetrioPharm GmbH, Berlin; Accredited and fully qualified lawyer; PhD in Political Sciences, TU Braunschweig; BSc in plant biotechnology, Hannover.

Financing Need

€2-3 M

Searching for

Commercial Partner, Funding, Collaboration


Pantherna Therapeutics GmbH